|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R,
Grannis FW Jr, et al: Non-small cell lung cancer, version 2.2013. J
Natl Compr Canc Netw. 11:645–653; quiz 653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamilton G and Rath B: Pharmacogenetics of
platinum-based chemotherapy in non-small cell lung cancer:
Predictive validity of polymorphisms of ERCC1. Expert Opin Drug
Metab Toxicol. 14:17–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forde PM and Ettinger DS: Targeted therapy
for non-small-cell lung cancer: Past, present and future. Expert
Rev Anticancer Ther. 13:745–758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cabanero M, Sangha R, Sheffield BS, Sukhai
M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts
C and Tsao MS: Management of EGFR-mutated non-small-cell
lung cancer: Practical implications from a clinical and pathology
perspective. Curr Oncol. 24:111–119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
González-Larriba JL, Lázaro-Quintela M,
Cobo M, Domine M, Majem M and García-Campelo R: Clinical management
of epidermal growth factor receptor mutation-positive non-small
cell lung cancer patients after progression on previous epidermal
growth factor receptor tyrosine kinase inhibitors: The necessity of
repeated molecular analysis. Transl Lung Cancer Res. 6 (Suppl
1):S21–S34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wada T, Qian XL and Greene MI:
Intermolecular association of the p185neu protein and EGF receptor
modulates EGF receptor function. Cell. 61:1339–1347. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carraway KL III and Cantley LC: A neu
acquaintance for erbB3 and erbB4: A role for receptor
heterodimerization in growth signaling. Cell. 78:5–8. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yarden Y: The EGFR family and its ligands
in human cancer. Signaling mechanisms and therapeutic
opportunities. Eur J Cancer. 37 (Suppl 4):S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Berezov A, Wang Q, Zhang G,
Drebin J, Murali R and Greene MI: ErbB receptors: From oncogenes to
targeted cancer therapies. J Clin Invest. 117:2051–2058. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seshacharyulu P, Ponnusamy MP, Haridas D,
Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway
in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arteaga C: Targeting HER1/EGFR: A
molecular approach to cancer therapy. Semin Oncol 30 (3 Suppl 7).
S3–S14. 2003.
|
|
13
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Araki T, Yashima H, Shimizu K, Aomori T,
Hashita T, Kaira K, Nakamura T and Yamamoto K: Review of the
treatment of non-small cell lung cancer with gefitinib. Clin Med
Insights Oncol. 6:407–421. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu Y, Liu H, Chen J and Zhou Q: Acquired
resistance of lung adenocarcinoma to EGFR-tyrosine kinase
inhibitors gefitinib and erlotinib. Cancer Biol Ther. 9:572–582.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guan Y, Cui ZJ, Sun B, Han LP, Li CJ and
Chen LM: Celastrol attenuates oxidative stress in the skeletal
muscle of diabetic rats by regulating the AMPK-PGC1α-SIRT3
signaling pathway. Int J Mol Med. 37:1229–1238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ju SM, Youn GS, Cho YS, Choi SY and Park
J: Celastrol ameliorates cytokine toxicity and pro-inflammatory
immune responses by suppressing NF-κB activation in RINm5F beta
cells. BMB Rep. 48:172–177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X, Wu N, Zou L and Jia D: Protective
effect of celastrol on myocardial ischemia-reperfusion injury.
Anatol J Cardiol. 18:384–390. 2017.PubMed/NCBI
|
|
19
|
Kashyap D, Sharma A, Tuli HS, Sak K,
Mukherjee T and Bishayee A: Molecular targets of celastrol in
cancer: Recent trends and advancements. Crit Rev Oncol Hematol.
128:70–81. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mi C, Shi H, Ma J, Han LZ, Lee JJ and Jin
X: Celastrol induces the apoptosis of breast cancer cells and
inhibits their invasion via downregulation of MMP-9. Oncol Rep.
32:2527–2532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rajendran P, Li F, Shanmugam MK, Kannaiyan
R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, et al:
Celastrol suppresses growth and induces apoptosis of human
hepatocellular carcinoma through the modulation of STAT3/JAK2
signaling cascade in vitro and in vivo. Cancer Prev Res (Phila).
5:631–643. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abbas S, Bhoumik A, Dahl R, Vasile S,
Krajewski S, Cosford ND and Ronai ZA: Preclinical studies of
celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res.
13:6769–6778. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yano S, Yamaguchi M and Dong RP: EGFR
tyrosine kinase inhibitor ‘gefitinib (Iressa)’ for cancer therapy.
Nihon Yakurigaku Zasshi. 122:491–497. 2003.(In Japanese).
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu F, Li J, Jang C, Wang J and Xiong J:
The role of Axl in drug resistance and epithelial-to-mesenchymal
transition of non-small cell lung carcinoma. Int J Clin Exp Pathol.
7:6653–6661. 2014.PubMed/NCBI
|
|
25
|
Bae SY, Hong JY, Lee HJ, Park HJ and Lee
SK: Targeting the degradation of AXL receptor tyrosine kinase to
overcome resistance in gefitinib-resistant non-small cell lung
cancer. Oncotarget. 6:10146–10160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dufies M, Jacquel A, Belhacene N, Robert
G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S and Auberger P:
Mechanisms of AXL overexpression and function in imatinib-resistant
chronic myeloid leukemia cells. Oncotarget. 2:874–885. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK,
Yoon SJ, Park BM, Park E, Bae JH, Choi CM and Lee JC: MET and AXL
inhibitor NPS-1034 exerts efficacy against lung cancer cells
resistant to EGFR kinase inhibitors because of MET or AXL
activation. Cancer Res. 74:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lemke G: Biology of the TAM receptors.
Cold Spring Harb Perspect Biol. 5:a0090762013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martinelli E, Martini G, Cardone C,
Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F,
Rinaldi B, Melillo RM, et al: AXL is an oncotarget in human
colorectal cancer. Oncotarget. 6:23281–23296. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qu X, Liu J, Zhong X, Li X and Zhang Q:
Role of AXL expression in non-small cell lung cancer. Oncol Lett.
12:5085–5091. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rankin EB, Fuh KC, Taylor TE, Krieg AJ,
Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ: AXL is
an essential factor and therapeutic target for metastatic ovarian
cancer. Cancer Res. 70:7570–7579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Giles KM, Kalinowski FC, Candy PA, Epis
MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ and Leedman PJ: Axl
mediates acquired resistance of head and neck cancer cells to the
epidermal growth factor receptor inhibitor erlotinib. Mol Cancer
Ther. 12:2541–2558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Xia H, Zhuang Z, Miao L, Chen X
and Cai H: Axl-altered microRNAs regulate tumorigenicity and
gefitinib resistance in lung cancer. Cell Death Dis. 5:e12272014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gioia R, Tregoat C, Dumas PY, Lagarde V,
Prouzet-Mauléon V, Desplat V, Sirvent A, Praloran V, Lippert E,
Villacreces A, et al: CBL controls a tyrosine kinase network
involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid
leukaemia. J Pathol. 237:14–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang WJ, Wang J, Tong X, Shi JB, Liu XH
and Li J: Design and synthesis of celastrol derivatives as
anticancer agents. Eur J Med Chem. 95:166–173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kuchta K, Xiang Y, Huang S, Tang Y, Peng
X, Wang X, Zhu Y, Li J, Xu J, Lin Z and Pan T: Celastrol, an active
constituent of the TCM plant Tripterygium wilfordii Hook.f.,
inhibits prostate cancer bone metastasis. Prostate Cancer Prostatic
Dis. 20:156–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bufu T, Di X, Yilin Z, Gege L, Xi C and
Ling W: Celastrol inhibits colorectal cancer cell proliferation and
migration through suppression of MMP3 and MMP7 by the PI3K/AKT
signaling pathway. Anticancer Drugs. 29:530–538. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee HW, Jang KS, Choi HJ, Jo A, Cheong JH
and Chun KH: Celastrol inhibits gastric cancer growth by induction
of apoptosis and autophagy. BMB Rep. 47:697–702. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou Y, Li W, Wang M, Zhang H, Tong X and
Xiao Y: Competitive profiling of celastrol targets in human
cervical cancer HeLa cells via quantitative chemical proteomics.
Mol Biosyst. 13:83–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu SW, Law BY, Mok SW, Leung EL, Fan XX,
Coghi PS, Zeng W, Leung CH, Ma DL, Liu L and Wong VK: Autophagic
degradation of epidermal growth factor receptor in
gefitinib-resistant lung cancer by celastrol. Int J Oncol.
49:1576–1588. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Liu Q, Chen H, You J, Peng B, Cao
F, Zhang X, Chen Q, Uzan G, Xu L and Zhang D: Celastrol improves
the therapeutic efficacy of EGFR-TKIs for non-small-cell lung
cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs.
29:748–755. 2018.PubMed/NCBI
|
|
42
|
Lo Iacono M, Monica V, Vavalà T, Gisabella
M, Saviozzi S, Bracco E, Novello S, Papotti M and Scagliotti GV:
ATF2 contributes to cisplatin resistance in non-small cell lung
cancer and celastrol induces cisplatin resensitization through
inhibition of JNK/ATF2 pathway. Int J Cancer. 136:2598–2609. 2015.
View Article : Google Scholar : PubMed/NCBI
|
